February 12, 2016—Amgen, the world’s largest biotechnology company by revenue, is giving 340B covered entities refunds stemming from “an adjustment of its 340B ceiling price” on nine of its 16 products, including its blockbusters Enbrel, Neulasta, and Prolia.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)